Trends In Life Sciences M&A: Cybersecurity And AI Take Center Stage

Complementary perspectives on the challenges and opportunities shaping healthcare M&A.In Belgium, the implementation of the EU's NIS2 Directive has elevated cybersecurity to a central concern in transactional due diligence.

Meanwhile, Switzerland is navigating the rise of artificial intelligence in healthcare, with existing laws already imposing significant obligations on companies deploying AI technologies.This article highlights how these developments are influencing deal strategy, compliance, and risk management in life sciences M&A.

Cybersecurity compliance in Belgian healthcare M&A

Belgium has taken a leading role in the EU by being the first Member State to transpose the NIS2 Directive into national law. This move has significantly raised the bar for cybersecurity compliance, particularly in the healthcare and life sciences sectors. The legislation is expected to impact over 2,500 entities, including hospitals, pharmaceutical manufacturers, and